<DOC>
	<DOCNO>NCT00552656</DOCNO>
	<brief_summary>The purpose study investigate long term efficacy safety firebird sirolimus-eluting stent treatment complex coronary Lesions .</brief_summary>
	<brief_title>Long Term Efficacy Safety Firebird Sirolimus-Eluting Stent In Complex Coronary Lesions</brief_title>
	<detailed_description>Randomized clinical trial large-scale registry study show sirolimus-eluting stent ( SESs ) decrease major adverse cardiovascular event ( MACE ) restenosis rate compare bare metal stent ( BMSs ) , relatively small proportion patient complex lesion enrol study . Moreover , increase complexity lesion , different DES show different effect . The long term effect DES treatment complex coronary lesion remain establish . This study aim investigate long term efficacy safety Firebird sirolimus-eluting stent implantation high-risk population , , patient complex coronary lesion , include multivessel disease , diffuse long lesion , leave main lesion , chronic total occlusion , bifurcation lesion , small vessel disease , severe calcification angulation lesion , ostial lesion , restenotic lesion bare metel stent implantation .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>patient indication coronary interventional therapy stable angina pectoris ( CCS class I II III IV ) unstable angina pectoris ( Braunwald class B＆C，III ) document asymptomatic myocardial ischemia reference vessel diameter 2.5mm 4.0mm ( estimate investigator ) significant ( &gt; 70 % ) stenosis target lesion ( estimate investigator ) angiographic criterion complex coronary lesion include following : multivessel lesion ( &gt; or=two vessel ) , diffuse long lesion length &gt; or=30mm need two stent overlap , small vessel lesion ( reference vessel diameter &lt; or=2.5mm estimate investigator ) , bifurcation lesion need one two stent side branch diameter &gt; 2.0mm , chronic total occlusion lesion ( &gt; 3 month ) , ostial target lesion ( include ostial right coronary artery , leave anterior descend artery leave circumflex artery ) , severe calcification angulation ( location target lesion &gt; 45°bend ) , protect unprotected leave main lesion , restenosis bare metal stent implantation ( core laboratory decision ) patient would like accept followup sign inform consent pregnant nursing woman acute myocardial infarction within precede one month graft lesion CABG implant drugeluting stent time except designate one left ventricle dysfunction ejection fraction &lt; 30 % ( evaluate echocardiogram Simpson 's doublechamber method ) renal dysfunction serum creatinine level &gt; or=2mg/dl ( 177umol/L ) preintervention intravascular brachytherapy nonPTCA technique contradiction allergy aspirin , heparin , clopidogrel , stainless steel hypersensitive contrast medium anticipate life span &lt; 12 month enrollment clinical trial time reach primary endpoint probably interference present trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Angioplasty , Transluminal , Percutaneous Coronary</keyword>
	<keyword>Drug-eluting stent</keyword>
	<keyword>Treatment Outcome</keyword>
</DOC>